Adrian Kinkaid
Chief Executive Officer, Fusion Antibodies
Adrian Kinkaid has over twenty-five years’ experience working in the bioscience sector. He holds a PhD in Biochemistry from University of Southampton and has expertise in development and commercialisation of all the main classes of affinity reagents. He joined Fusion Antibodies as CEO in August 2022. Adrian’s previous experience has included senior management positions in drug discovery, reagent technology and diagnostics. He is passionate about harnessing biotechnology to create better drugs and diagnostics in order to improve health and wellbeing on a global scale.
